Skip to content
Massachusetts Eye and Ear
/assets/MEE/images/mgb-default-thumb.png News


Advancing a Novel Experimental Gene-based COVID-19 Vaccine, AAVCOVID

Leading the efforts are Luk Vandenberghe, PhD, Mass. Eye and Ear, Mason Freeman, MD, Mass General, and James M. Wilson, MD, PhD, Perelman School of Medicine at the University of Pennsylvania. The multi-institutional research project is working to develop and test a COVID-19 vaccine based on AAV gene transfer technology with the goal of entering clinical testing this year.

When the genetic sequences of the novel coronavirus were published in January of 2020, Dr. Vandenberghe began developing and testing genetic vaccines for the virus in his laboratory. His approach uses a unique adeno-associated virus (AAV) vector that he developed years ago and has proven to be an effective vaccine carrier that is applicable to broad populations. The unique advantages of the AAV are its clinical safety record of more than 25 years and a large AAV industry that can be leveraged for fast deployment of a potential vaccine.

Read the full press release

Academic-Industry Partnerships

AAVCOVID vaccine program, a novel experimental gene-based COVID-19 vaccine that is the only approach based on adeno-associated virus (AAV) gene transfer technology, is working with various partners that will help the program reach its goal of a vaccine with potential for scalability to enter clinical trials. Learn more about the team members:

About Our Researchers

Philanthropic Support

Philanthropy is playing a significant role in accelerating the AAVCOVID vaccine project, building off initial support from the Mass. Eye and Ear Board of Directors. Fundraising for more milestones along the AAVCOVID development will explore additional philanthropy, grants, support from the Mass General Brigham Innovation Fund, foundation, and commercial partners. 

Please visit here for more information if you are interested in getting involved.

Media Coverage